Form 4: Cognex EVP Carl Gerst Sells All Common Stock Holdings
Insider Transaction Report
Carl Gerst, EVP of Global Sales and Products at Cognex Corp, disposed of all his directly held common stock, totaling 10,532 shares, following RSU vestings.
Summary
- Carl Gerst, EVP, Global Sales and Products at Cognex Corp, reported multiple transactions involving the company's common stock.
- On February 20, 2026, 6,846 restricted stock units (RSUs) vested, resulting in an acquisition of common stock.
- On February 21, 2026, an additional 8,791 restricted stock units (RSUs) vested, resulting in an acquisition of common stock.
- A total of 5,105 shares were withheld to satisfy tax obligations related to the RSU vestings (2,010 shares on February 20 and 3,095 shares on February 21).
- Gerst sold 3,804 shares on February 20, 2026, at an average price of $55.9883 per share.
- Gerst sold his remaining 10,532 shares on February 23, 2026, at an average price of $55.9288 per share.
- All open market sales were conducted pursuant to a Rule 10b5-1 trading plan.
- Following these transactions, Gerst's direct beneficial ownership of Cognex common stock is 0 shares.
- Gerst continues to hold various non-qualified stock options and unvested restricted stock units.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a moderately negative signal due to a key executive divesting all direct common stock holdings, even if executed under a pre-planned 10b5-1 arrangement. While RSU vesting is a positive for the executive, the subsequent full sale of direct shares could raise questions about future confidence.
Positives
- The vesting of 15,637 Restricted Stock Units (RSUs) indicates the fulfillment of long-term incentive compensation for the executive.
Negatives
- Carl Gerst, EVP, Global Sales and Products, disposed of all his directly held common stock, resulting in 0 shares beneficially owned directly.
- A total of 14,336 shares were sold in open market transactions.
- The significant reduction in direct ownership by a key executive could be perceived negatively by investors.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence, especially when it results in a complete divestment of direct common stock holdings by a key executive. This action occurs within the broader context of the industrial automation and machine vision industry, where Cognex operates, and could be viewed in light of current or anticipated sector performance.
Stakeholder Impact
- Shareholders: May interpret the complete divestment of direct common stock by a key executive as a negative signal regarding future company performance or executive confidence, potentially leading to downward pressure on the stock price.
- Employees: No direct impact mentioned, but could indirectly affect morale if perceived as a lack of executive commitment.
Next Steps
- Continued vesting of remaining Restricted Stock Units on their respective anniversary dates (e.g., 02/18/2026, 02/17/2027).
- Potential exercise of various Non-Qualified Stock Options held by the reporting person, which have different exercise and expiration dates.
Key Dates
| Date | Description |
|---|---|
| 02/19/2020 | Date exercisable for 60,000 Non-Qualified Stock Options with an exercise price of $51.49. |
| 02/18/2021 | Date exercisable for 80,000 Non-Qualified Stock Options with an exercise price of $50.94. |
| 02/21/2023 | Grant date for 8,791 Restricted Stock Units, vesting 20%, 30%, and 50% on the first, second, and third anniversaries, respectively. |
| 02/22/2023 | Date exercisable for 74,720 Non-Qualified Stock Options with an exercise price of $64.43. |
| 02/20/2024 | Grant date for 6,846 Restricted Stock Units, vesting 20%, 30%, and 50% on the first, second, and third anniversaries, respectively. |
| 02/21/2024 | Date exercisable for 94,298 Non-Qualified Stock Options with an exercise price of $47.21. |
| 02/20/2025 | Date exercisable for 126,800 Non-Qualified Stock Options with an exercise price of $39.44. |
| 10/30/2025 | Date exercisable for 150,000 Non-Qualified Stock Options with an exercise price of $65.9. |
| 02/18/2026 | Date exercisable for 75,871 Non-Qualified Stock Options with an exercise price of $33.04. Also, the date for 22,276 Restricted Stock Units. |
| 02/20/2026 | Transaction date for vesting of 6,846 RSUs, tax withholding of 2,010 shares, and open market sale of 3,804 shares. |
| 02/21/2026 | Transaction date for vesting of 8,791 RSUs and tax withholding of 3,095 shares. |
| 02/23/2026 | Transaction date for open market sale of 10,532 shares. |
| 02/24/2026 | Signature date of the reporting person. |
| 02/17/2027 | Date exercisable for 24,854 Non-Qualified Stock Options with an exercise price of $57.09. Also, the date for 24,085 Restricted Stock Units. |
| 02/20/2027 | Expiration date for 6,846 Restricted Stock Units granted on 02/20/2024. |
| 02/18/2028 | Expiration date for 22,276 Restricted Stock Units. |
| 02/20/2028 | Expiration date for 20,000 Non-Qualified Stock Options with an exercise price of $56.44. |
| 02/17/2029 | Expiration date for 24,085 Restricted Stock Units. |
| 02/19/2029 | Expiration date for 60,000 Non-Qualified Stock Options with an exercise price of $51.49. |
| 02/18/2030 | Expiration date for 80,000 Non-Qualified Stock Options with an exercise price of $50.94. |
| 10/30/2030 | Expiration date for 150,000 Non-Qualified Stock Options with an exercise price of $65.9. |
| 02/22/2032 | Expiration date for 74,720 Non-Qualified Stock Options with an exercise price of $64.43. |
| 02/21/2033 | Expiration date for 94,298 Non-Qualified Stock Options with an exercise price of $47.21. |
| 02/20/2034 | Expiration date for 126,800 Non-Qualified Stock Options with an exercise price of $39.44. |
| 02/18/2035 | Expiration date for 75,871 Non-Qualified Stock Options with an exercise price of $33.04. |
| 02/17/2036 | Expiration date for 24,854 Non-Qualified Stock Options with an exercise price of $57.09. |
Recommendation
sellThe complete divestment of all directly held common stock by a high-ranking executive, Carl Gerst, EVP of Global Sales and Products, is a strong negative signal. While the sales were conducted under a 10b5-1 plan, the decision to liquidate all direct holdings, even after RSU vestings, suggests a lack of conviction in the company's near-term or long-term stock performance. Seasoned investors typically view such actions by insiders as a reason to re-evaluate their own positions, as executives often have superior insight into the company's prospects. This move warrants a 'sell' recommendation for investors holding the stock, or a 'avoid' for those considering entry, until clearer positive signals emerge.
Keywords
Cognex Corp, CGNX, Insider Trading, Form 4, Carl Gerst, Stock Sale, Restricted Stock Units, 10b5-1 Plan, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.